First preschool-aged child receives arpraziquantel, the new pediatric treatment option for schistosomiasis, through an implementation research study

第一名学龄前儿童通过实施研究接受了治疗血吸虫病的新型儿科药物——阿普拉喹酮。

Arpraziquantel completes the range of treatments for the neglected tropical disease schistosomiasis in all age groups

阿尔布拉苯达唑完成了所有年龄组被忽视的热带病血吸虫病的治疗范围。

Merck is focusing on disease control to eliminate schistosomiasis, the second most dangerous parasitic disease (after malaria) in the world, as a public health problem by 2030

默克公司正专注于疾病控制，目标是到2030年消除血吸虫病这一世界第二大危险的寄生虫病（仅次于疟疾）作为公共卫生问题。

Merck, a leading science and technology company, and the

默克，一家领先的科学和技术公司，以及

Pediatric Praziquantel Consortium

儿童吡喹酮联盟

today announced that the first preschool-aged child has been treated with arpraziquantel in an implementation research study in Uganda. Arpraziquantel is a newly developed pediatric treatment option for the neglected tropical disease schistosomiasis. This disease is caused by parasitic worms, and it is estimated that over 250 million people are affected..

今天宣布，在乌干达的一项实施研究中，首次对学龄前儿童使用了阿普拉喹酮进行治疗。阿普拉喹酮是一种新开发的针对被忽视的热带病血吸虫病的儿科治疗选择。这种疾病是由寄生虫引起的，估计有超过2.5亿人受到影响。

“With the successful introduction of arpraziquantel to preschool-aged children in the first African nation, we have reached a critical milestone in making treatments for schistosomiasis available to all age groups,” said Peter Guenter, Member of the Executive Board and CEO Healthcare at Merck. “In partnership with the Pediatric Praziquantel Consortium, Merck has been steadfast in its commitment to combating schistosomiasis.

“随着阿普拉喹酮成功引入非洲第一个国家的学龄前儿童，我们在实现让所有年龄组都能获得血吸虫病治疗的目标上达到了一个关键里程碑，”默克公司执行董事会成员兼医疗保健首席执行官彼得·冈特表示。“通过与儿科吡喹酮联盟的合作，默克始终坚定地致力于抗击血吸虫病。”

We remain focused on accelerating disease control efforts, with the ultimate goal of eliminating schistosomiasis as a public health threat by 2030.”.

我们将继续专注于加快疾病控制的努力，最终目标是到2030年消除血吸虫病作为公共卫生威胁。

Derived from praziquantel, the standard of care treatment for school-aged children and adults, arpraziquantel is a 150mg dispersible tablet, designed for preschool-aged children with an acceptable taste and withstanding the hot and humid conditions of tropical climates. Arpraziquantel was granted the .

源于吡喹酮，这是针对学龄儿童和成人治疗的标准药物，arpraziquantel是一种150毫克的分散片，专为学龄前儿童设计，具有可接受的口味，并能耐受热带气候的高温高湿条件。Arpraziquantel已获得 。

positive scientific opinion by the European Medicines Agency (EMA)

欧洲药品管理局 (EMA) 的积极科学意见

and included into the

并包含到

World Health Organization (WHO)’s List of Prequalified Medicinal Products

世界卫生组织（WHO）预认证药品清单

respectively in December 2023 and May 2024. Inclusion into the WHO’s List of Essential Medicines is expected in 2025. In parallel, technology transfer from Merck to Universal Corporation Ltd. (Nairobi, Kenya) is ongoing for planned future large-scale local production; new procurement and funding mechanisms are collaboratively defined for equitable and sustainable access to the new medication..

分别在2023年12月和2024年5月。预计将在2025年被列入世界卫生组织基本药物清单。与此同时，默克公司正向环球公司（肯尼亚内罗毕）进行技术转让，以计划未来大规模本地生产；新的采购和资金机制正在协同制定中，以确保公平且可持续地获取新药。

As part of the Consortium’s

作为联盟的组成部分

ADOPT

采用

program, the introduction of arpraziquantel is supported by the Ministry of Health in Uganda through an implementation research study in a mass drug administration setting for children aged two to five years. The overall aim of this ADOPT study led by Consortium partners, Unlimit Health (London, United Kingdom) and the Swiss Tropical and Public Health Institute (Allschwil, Switzerland), is to identify routine practices for a wider adoption of the new medication into countries where schistosomiasis is endemic.

通过在2至5岁儿童群体中实施大规模药物管理研究，乌干达卫生部支持引入arpraziquantel。这项由联盟合作伙伴Unlimit Health（英国伦敦）和瑞士热带与公共卫生研究所（瑞士阿尔施维尔）主导的ADOPT研究的总体目标是，确定将这种新药更广泛纳入血吸虫病流行国家的常规实践方法。

Merck is the product supplier for this study. Beyond Uganda, introduction of arpraziquantel will be extended to other sub-Saharan African countries to start with Côte d’Ivoire, Kenya, Tanzania and Senegal..

默克公司是这项研究的产品供应商。除了乌干达，引入阿普拉喹还将扩展到其他撒哈拉以南非洲国家，首先是在科特迪瓦、肯尼亚、坦桑尼亚和塞内加尔。

Merck initiated its ‘Schistosomiasis Elimination Program’ in cooperation with WHO back in 2007. Through this initiative, Merck supports the requirements of the WHO’s 2021-2030 Roadmap for Neglected Tropical Diseases and the United Nations’ Sustainable Goals, in line with the company’s sustainability strategy and its engagement to drive health equity.

默克公司于2007年与世界卫生组织合作发起了“消除血吸虫病计划”。通过这一倡议，默克支持世界卫生组织2021-2030年被忽视热带病路线图及联合国可持续发展目标的要求，该计划与公司的可持续发展战略及其推动健康公平的承诺保持一致。

Each year, Merck provides up to 250 million tablets of praziquantel. In partnership with WHO, Merck has donated over 2 billion tablets of praziquantel so far, enabling the treatment of more than 800 million people, primarily school-aged children..

每年，默克公司提供多达2.5亿片吡喹酮。通过与世界卫生组织的合作，默克公司迄今已捐赠了超过20亿片吡喹酮，使得超过8亿人，主要是学龄儿童，得到了治疗。